Tuhura Biosciences Inc (HURA)

Aug 20, 2025, 8:00 AM EDT - 3 days ago

TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference

Aug 14, 2025, 4:15 PM EDT - 9 days ago

TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Jul 10, 2025, 4:00 AM EDT - 6 weeks ago

Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development

Jul 1, 2025, 8:50 AM EDT - 7 weeks ago

TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Jun 30, 2025, 8:50 AM EDT - 7 weeks ago

TuHURA Biosciences Completes Acquisition of Kineta

Jun 24, 2025, 8:00 AM EDT - 2 months ago

TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma

Jun 23, 2025, 5:00 PM EDT - 2 months ago

TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals

Jun 9, 2025, 8:00 AM EDT - 2 months ago

FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma

Jun 3, 2025, 9:58 AM EDT - 2 months ago

TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy

Jun 2, 2025, 8:03 AM EDT - 2 months ago

TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting

May 15, 2025, 4:10 PM EDT - 3 months ago

TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update

May 13, 2025, 8:00 AM EDT - 3 months ago

TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference

May 5, 2025, 8:00 AM EDT - 3 months ago

TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)

Apr 28, 2025, 8:00 AM EDT - 4 months ago

TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting

Apr 8, 2025, 8:00 AM EDT - 4 months ago

TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting

Apr 7, 2025, 8:24 AM EDT - 4 months ago

TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management

Apr 1, 2025, 8:00 AM EDT - 5 months ago

TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Mar 11, 2025, 8:05 AM EDT - 5 months ago

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D.

Mar 10, 2025, 9:00 AM EDT - 5 months ago

TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference

Feb 19, 2025, 9:00 AM EST - 6 months ago

TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Dec 20, 2024, 10:18 AM EST - 8 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTS and HURA on Behalf of Shareholders

VTS

Dec 12, 2024, 8:45 AM EST - 9 months ago

TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.

Nov 25, 2024, 8:35 AM EST - 9 months ago

TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update

Oct 23, 2024, 8:30 AM EDT - 10 months ago

TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

Oct 22, 2024, 9:00 AM EDT - 10 months ago

TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event

Oct 17, 2024, 4:35 PM EDT - 11 months ago

TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics

Oct 16, 2024, 12:54 PM EDT - 11 months ago

Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024

Oct 16, 2024, 11:58 AM EDT - 11 months ago

Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences

Oct 15, 2024, 4:15 PM EDT - 11 months ago

Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

Oct 14, 2024, 8:30 AM EDT - 11 months ago

Kintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

Oct 8, 2024, 7:00 AM EDT - 11 months ago

Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update

Sep 20, 2024, 9:25 AM EDT - 1 year ago

Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024

Sep 18, 2024, 8:30 AM EDT - 1 year ago

Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences

Sep 11, 2024, 8:30 AM EDT - 1 year ago

Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study

Sep 9, 2024, 8:30 AM EDT - 1 year ago

Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc.

Aug 19, 2024, 9:00 AM EDT - 1 year ago

TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

Jul 8, 2024, 6:30 AM EDT - 1 year ago

TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor

Jul 1, 2024, 8:35 AM EDT - 1 year ago

Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones

Jun 3, 2024, 8:35 AM EDT - 1 year ago

TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)

May 14, 2024, 4:45 PM EDT - 1 year ago

Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results

Apr 5, 2024, 1:31 PM EDT - 1 year ago

KINTARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Kintara Therapeutics, Inc. - KTRA

Apr 3, 2024, 7:00 AM EDT - 1 year ago

Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement

Mar 27, 2024, 9:00 AM EDT - 1 year ago

Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab

Feb 14, 2024, 4:07 PM EST - 1 year ago

Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update

Feb 12, 2024, 9:00 AM EST - 1 year ago

Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer

Jan 2, 2024, 7:06 AM EST - 1 year ago

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains in January - Corcept Therapeutics (NASDAQ:CORT), Kintara Therapeutics (NASDAQ:KTRA)

CORT MIST RPID

Dec 18, 2023, 7:39 AM EST - 1 year ago

Top 3 Health Care Stocks That Are Preparing To Pump This Month - Durect (NASDAQ:DRRX), Aadi Bioscience (NASDAQ:AADI)

DRRX